- Record: found
- Abstract: not found
- Article: not found
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
Craig T January ,
L Samuel Wann ,
Hugh Calkins ,
Lin Y Chen ,
Joaquin E Cigarroa ,
Joseph C Cleveland ,
Patrick T Ellinor ,
Michael D Ezekowitz ,
Michael E Field ,
Karen L Furie ,
Paul A Heidenreich ,
Katherine T Murray ,
Julie B Shea ,
Cynthia M Tracy ,
Clyde W Yancy
July 09 2019
ACC/AHA Clinical Practice Guidelines,
acute coronary syndrome,
anticoagulants,
anticoagulation agents,
antiplatelet agents,
apixaban,
atrial fibrillation,
atrial flutter,
cardioversion,
coronary artery disease,
coronary heart disease,
dabigatran,
edoxaban,
focused update,
hypertension,
idarucizumab,
myocardial infarction,
obesity,
percutaneous coronary intervention,
risk factors,
rivaroxaban,
sleep apnea,
stents,
stroke,
thromboembolism,
warfarin
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Author and article information
ACC/AHA Clinical Practice Guidelines,acute coronary syndrome,anticoagulants,anticoagulation agents,antiplatelet agents,apixaban,atrial fibrillation,atrial flutter,cardioversion,coronary artery disease,coronary heart disease,dabigatran,edoxaban,focused update,hypertension,idarucizumab,myocardial infarction,obesity,percutaneous coronary intervention,risk factors,rivaroxaban,sleep apnea,stents,stroke,thromboembolism,warfarin
ACC/AHA Clinical Practice Guidelines, acute coronary syndrome, anticoagulants, anticoagulation agents, antiplatelet agents, apixaban, atrial fibrillation, atrial flutter, cardioversion, coronary artery disease, coronary heart disease, dabigatran, edoxaban, focused update, hypertension, idarucizumab, myocardial infarction, obesity, percutaneous coronary intervention, risk factors, rivaroxaban, sleep apnea, stents, stroke, thromboembolism, warfarin